How to Buy Seres Therapeutics Stock
Seres Therapeutics Inc
Seres Therapeutics, Inc. , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.
Seres Therapeutics stock last closed at $2.61, down 4.04% from the previous day, and has decreased 56.72% in one year. It has underperformed other stocks in the Biotechnology industry by 0.24 percentage points. Seres Therapeutics stock is currently +0.38% from its 52-week low of $2.60, and -72.5% from its 52-week high of $9.49.
There are currently 128.2M MCRB shares outstanding. The market capitalization of MCRB is $334.61M. In the last 24 hours, 2.27M MCRB shares were traded.
How to Buy Seres Therapeutics Stock
Wondering how to invest in Seres Therapeutics stock? Here's how.
- Choose where to buy Seres Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you determine where to buy Seres Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Pick your payment method and add your details.
- Research Seres Therapeutics stock: The Seres Therapeutics ticker symbol is MCRB. Is Seres Therapeutics stock a good investment? Should you buy shares of MCRB? How do MCRB's underlying business fundamentals look? Do top analysts think Seres Therapeutics is a good buy? Why has MCRB's stock price moved recently? (Hint: Our stock research tools can help you figure out if MCRB is a good stock to buy).
- Execute your MCRB trade: Decide if you will purchase MCRB shares at the current market price or use a limit order to purchase MCRB shares at a given price.
- Get the latest scoop on your MCRB position: Create a watchlist to important updates regarding your new investment in Seres Therapeutics stock.
Step 1: Choose where to buy Seres Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy MCRB stock.
Our recommended brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global financial markets: From Technology to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal information so you can buy MCRB stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.
- Provide your personal info to open your new brokerage account.
- Send your data by clicking the "Create Account" button.
Step 3: Fund your investment account
Now that you have filled out your info on the best stock app, you need to deposit funds:
Watch the video below to see the process of transferring money into your new investment account.
Step 4: Research Seres Therapeutics stock
Once you have identified the best place to buy Seres Therapeutics stock, it's absolutely critical to evaluate their stock prior to buying, so you truly understand the risk and opportunity.
Seres Therapeutics Numbers
MCRB Fundamentals
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on MCRB's stock page.
What is the fair value of MCRB stock?
Investors use many financial metrics, analyses, models, and charts to gauge MCRB's true value.
Using relative valuations methods:
- MCRB may be overvalued based on its P/B ratio of 14.8x, relative to Biotechnology industry P/B ratio of 5.11x
You can access more valuation research on MCRB's stock here.
MCRB Financial Health
Passed Health Checks:
- MCRB has cash burn of 133083000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the MCRB balance sheet.
- Total MCRB debt is lower than 5 years ago, relative to shareholder equity.
Failed Health Checks:
- MCRB profit margin has gone down from -75.5% to -117.7% in the past year.
- There are more long-term liabilities than short-term assets on the MCRB balance sheet.
- MCRB has $237.71M in cash and short term investments. This is not enough to cover its annual cash burn of $133.08M.
- MCRB has a relatively high debt to equity ratio of 16.97.
Do analysts think it's a good time to buy Seres Therapeutics stock
Out of 3 sell side analysts who give recommendations on MCRB, the consensus analyst rating on Seres Therapeutics is a Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent MCRB Analyst Upgrades/Downgrades
Mark Breidenbach, a bottom 11% analyst from Oppenheimer assumes MCRB with a buy rating and announces their MCRB price target of $12.00, on Jun 26, 2023.
Keay Nakae, a top 9% analyst from Chardan Capital maintains MCRB with a strong buy rating and lowers their MCRB price target from $12.00 to $10.00, on Apr 28, 2023.
Tessa Romero, a bottom 4% analyst from JP Morgan initiates coverage on MCRB with a hold rating and announces their MCRB price target of $7.00, on Apr 21, 2023.
You can dig deeper into what analysts are projecting on the Seres Therapeutics stock forecast page.
Metrics for Advanced MCRB Traders
MCRB Growth Metrics
Last year, MCRB revenue was $130.37M. During the past five year, MCRB's revenue has grown by 30.34% per year. This was slower than the Biotechnology industry average of 108.03%.
Learn more about MCRB's earnings and revenue performance here.
Who is buying/selling MCRB?
In the past 12 months, insiders at MCRB have sold more shares than they have bought.
David S. Ege, Executive Vice President and Chief Technology Officer of MCRB, was the latest MCRB insider to sell. They sold $36,527.22 worth of MCRB stock on Apr 28, 2023.
Dig into more about who owns MCRB shares here.
Does MCRB provide a stable income stream?
No, Seres Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your MCRB trade
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Press the Open button and your broker will place your order.
If you need additional help buying stocks on eToro, click the how to video below:
Step 6: Get the latest scoop on your MCRB position
Now that you own some MCRB shares, you'll want to keep up with your new investment.
Make a watchlist to get alerted to the latest events about your MCRB stock.
MCRB Feed
How to Buy Stock in Seres Therapeutics
To reiterate, here are the 6 steps for buying Seres Therapeutics stock:
- Choose where to buy Seres Therapeutics stock
- Open a brokerage account
- Fund your investment account
- Research Seres Therapeutics stock
- Execute your MCRB trade
- Get the latest scoop on your MCRB position
If you are looking for a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Seres Therapeutics, create a watchlist on WallStreetZen today.
More Articles You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.